Latest & greatest articles for menopause

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on menopause or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on menopause and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for menopause

41. A review of effective herbal medicines in controlling menopausal symptoms (PubMed)

A review of effective herbal medicines in controlling menopausal symptoms Acute menopausal syndrome especially hot flashes, is one of the most common gynecological problems during menopause. Due to the side effects of hormone therapy, herbal and complementary medicines are always of immense interest to people in the treatment and management of the symptoms and complications of menopause.The aim of this study was to investigate the mechanisms and effects of medicinal plants employed (...) in the treatment of menopausal symptoms.This review article was carried out by examining clinical trial studies between the period of 1994 and 2016. The keywords, which include menopause, climacteric, hot flushes, flashes, herb and phytoestrogens were used to search for herbal medicines used in clinical trials for the treatment of menopausal symptoms using databases such as PubMed, Medline, Scopus, Google scholar, SID and Magiran.The results of the study showed that the medicinal plants, which include Sage

Full Text available with Trip Pro

2017 Electronic physician

42. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. (PubMed)

Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. No clinical trials have compared osteoporosis drugs with incident fractures as the primary outcome. We compared the anti-fracture efficacy of teriparatide with risedronate in patients with severe osteoporosis.In this double-blind, double-dummy trial, we enrolled post-menopausal women with at least two moderate (...) in the risedronate group (hazard ratio 0·48, 95% CI 0·32-0·74; p=0·0009). Non-vertebral fragility fractures occurred in 25 (4·0%) patients in the teriparatide group and 38 (6·1%) in the risedronate group (hazard ratio 0·66; 95% CI 0·39-1·10; p=0·10).Among post-menopausal women with severe osteoporosis, the risk of new vertebral and clinical fractures is significantly lower in patients receiving teriparatide than in those receiving risedronate.Lilly.Copyright © 2018 Elsevier Ltd. All rights reserved.

2017 Lancet

43. Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women's Health Initiative Randomized Trials. (PubMed)

Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women's Health Initiative Randomized Trials. Health outcomes from the Women's Health Initiative Estrogen Plus Progestin and Estrogen-Alone Trials have been reported, but previous publications have generally not focused on all-cause and cause-specific mortality.To examine total and cause-specific cumulative mortality, including during the intervention and extended postintervention follow-up, of the 2 Women's

Full Text available with Trip Pro

2017 JAMA

44. Risk of Stroke With Various Types of Menopausal Hormone Therapies: A National Cohort Study

Risk of Stroke With Various Types of Menopausal Hormone Therapies: A National Cohort Study Double-blind randomized studies on the effects of oral postmenopausal hormone therapies were stopped mainly because of increased risk of stroke. We aimed to assess the risk of all strokes and various subtypes associated with hormone therapy and explore the influence of regimens and routes of administration.A national historical cohort of women aged 51 to 70 years from 1995 to 2010 was established

Full Text available with Trip Pro

2017 EvidenceUpdates

45. Equine oestrogens + bazedoxifene (Duavive) and menopause. Inadequately evaluated harms

Equine oestrogens + bazedoxifene (Duavive) and menopause. Inadequately evaluated harms Prescrire IN ENGLISH - Spotlight ''Equine oestrogens + bazedoxifene (Duavive°) and menopause. Inadequately evaluated harms'', 1 July 2017 {1} {1} {1} | | > > > Equine oestrogens + bazedoxifene (Duavive°) and menopause. Inadequately evaluated harms Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |  (...)  |   |  Spotlight Equine oestrogens + bazedoxifene (Duavive°) and menopause. Inadequately evaluated harms FEATURED REVIEW A new product combining equine oestrogens and bazedoxifene (Duavive°, Pfizer) has been authorised in the European Union for menopausal disorders in non-hysterectomised postmenopausal women. Past experience suggests that this new combination should be considered with caution, and avoided until these foreseeable adverse effects have been properly evaluated. Full

2017 Prescrire

46. Neurokinin 3 receptor antagonism as a novel treatment for menopausal hot flushes: a phase 2, randomised, double-blind, placebo-controlled trial. (PubMed)

Neurokinin 3 receptor antagonism as a novel treatment for menopausal hot flushes: a phase 2, randomised, double-blind, placebo-controlled trial. Hot flushes affect 70% of menopausal women and often severely impact physical, psychosocial, sexual, and overall wellbeing. Hormone replacement therapy is effective but is not without risk. Neurokinin B signalling is increased in menopausal women, and has been implicated as an important mediator of hot flushes.This phase 2, randomised, double-blind (...) , placebo-controlled, single-centre, crossover trial assessed the effectiveness of an oral neurokinin 3 receptor antagonist (MLE4901) on menopausal hot flushes. Eligible participants were healthy women aged 40-62 years, having seven or more hot flushes in every 24 h of which some were reported as being severe or bothersome, who had not had a menstrual period for at least 12 months, and who had not been taking any medication shown to improve menopausal flushes in the preceding 8 weeks. Participants

Full Text available with Trip Pro

2017 Lancet

47. The Relationship between Physical Activity and General Health among Menopausal Women in Ahvaz, Iran (PubMed)

The Relationship between Physical Activity and General Health among Menopausal Women in Ahvaz, Iran Most women experience significant changes in their general health status during menopause, which negatively affects their quality of life. Physical activity has also been shown to enhance quality of life. However, little is known about the effect of physical activity on women's health during the menopausal transition. This study aimed to determine the relationship between physical activity (...) and general health among menopausal women in Ahvaz, Iran.This cross sectional study was carried out on 600 menopausal women using cluster random sampling during 2013-2014. Data collection tools were three questionnaires; women's demographic characteristics, the Goldenberg's questionnaire, and International physical activity questionnaire (IPAQ). Data were analyzed using descriptive and inferential statistics through SPSS version 19. The statistical tests were performed at the 95% confidence interval.There

Full Text available with Trip Pro

2017 Electronic physician

48. Examining Psychometric Characteristics of a Menopausal Health Questionnaire: Translation and Psychometric Evaluation of the Persian Version (PubMed)

Examining Psychometric Characteristics of a Menopausal Health Questionnaire: Translation and Psychometric Evaluation of the Persian Version Menopause is a natural event in a woman's life which affects her general health and quality of life. However, currently there is no Persian instrument for measuring health status during this period. Therefore, the present study was performed to assess the validity and reliability of the Persian version of the Menopausal Health Questionnaire in Iran.The (...) correlation coefficient (ICC) was assessed to be 0.93.The 14-item Menopausal Health Questionnaire is a valid and reliable instrument to assess postmenopausal women's health.

Full Text available with Trip Pro

2017 Electronic physician

49. Management of menopausal symptoms in women with a history of breast cancer

Management of menopausal symptoms in women with a history of breast cancer Management of menopausal symptoms in women with a history of breast cancer Management of menopausal symptoms in women with a history of breast cancer December 2016 | Incorporates published evidence to November 2015 This guideline includes Evidence Summaries and Recommendations based on available evidence about the effectiveness and safety of different therapies for managing menopausal symptoms in women after breast (...) cancer. The guideline provides health professionals and breast cancer patients with information to support decisions regarding the choice of particular therapies for the management of menopausal symptoms in the context of past or ongoing treatment for breast cancer. © Cancer Australia 2016 Management of menopausal symptoms in women with a history of breast cancer page 1 of 181Table of contents Management of menopausal symptoms in women with a history of breast cancer 1 Background 5 Grading

2017 Cancer Australia

53. The 2017 hormone therapy position statement of The North American Menopause Society

The 2017 hormone therapy position statement of The North American Menopause Society Copyright @ 2017 The North American Menopause Society. Unauthorized reproduction of this article is prohibited. POSITION STATEMENT The 2017 hormone therapy position statement of The North American Menopause Society Abstract The2017HormoneTherapyPositionStatementofTheNorthAmericanMenopauseSociety(NAMS)updatesthe 2012HormoneTherapyPositionStatementofTheNorthAmericanMenopauseSocietyandidentifiesfutureresearch needs (...) . An Advisory Panel of clinicians and researchers expert in the field of women’s health and menopause was recruited by NAMS to review the 2012 Position Statement, evaluate new literature, assess the evidence, and reach consensusonrecommendations,usingthelevelofevidencetoidentifythestrengthofrecommendationsandthequality of the evidence. The Panel’s recommendations were reviewed and approved by the NAMS Board of Trustees. Hormone therapy (HT) remains the most effective treatment for vasomotor symptoms (VMS

2017 The North American Menopause Society

54. Parkinsonism, premature menopause, and mitochondrial DNA polymerase gamma mutations: clinical and molecular genetic study. (PubMed)

Parkinsonism, premature menopause, and mitochondrial DNA polymerase gamma mutations: clinical and molecular genetic study. Mutations in the gene encoding mitochondrial DNA polymerase gamma (POLG), the enzyme that synthesises mitochondrial DNA (mtDNA), have been associated with a mitochondrial disease-autosomal dominant or recessive progressive external ophthalmoplegia-and multiple deletions of mtDNA. Mitochondrial dysfunction is also suspected to participate in the pathogenesis of Parkinson's (...) emission tomography (PET).We recorded mutations in POLG in members of all seven families. Clinical assessment showed significant cosegregation of parkinsonism with POLG mutations (p<0.0001), and PET findings were consistent with dopaminergic neuron loss. Post-mortem examination in two individuals showed loss of pigmented neurons and pigment phagocytosis in substantia nigra without Lewy bodies. Furthermore, most women with progressive external ophthalmoplegia had early menopause-before age 35 years

2017 Lancet

55. Cognitive Behaviour Therapy (CBT) for Menopausal Symptoms

Cognitive Behaviour Therapy (CBT) for Menopausal Symptoms BRITISH MENOPAUSE SOCIETY T ool for clinicians Information for GPs and other health professionals 1 of 2 Cognitive Behaviour Therapy (CBT) for Menopausal Symptoms Cognitive Behaviour Therapy (CBT) for Menopausal Symptoms The Menopause Guideline (National Institute for Health and Care Excellence, NICE 2015; 1.3.3) recommends that GPs and health professionals give information and advice to menopausal women about cognitive behaviour therapy (...) . Anxiety and stress – NICE (201 5) 1 recommends CBT as a treatment option for anxiety experienced by women during the menopause transition and post menopause. Women can feel anxious at this time, due to unpredictable hot flushes and social embarrassment, which can lead to avoidance of social and other activities. Hot flushes can be associated with palpitations. Bearing these issues in mind CBT can be adapted from protocols for social and general anxiety. Depressed mood – NICE (201 5) recommends CBT

2017 British Menopause Society

56. Non-hormonal-based treatments for menopausal symptoms

Non-hormonal-based treatments for menopausal symptoms Non-hormonal-based treatments for menopausal symptoms | British Menopause Society Search for: Summary consensus statement Non-hormonal-based treatments for menopausal symptoms Non-hormonal-based treatments for menopausal symptoms 2018-04-13T10:06:04+01:00 Summary practice points As clinicians we must be familiar with alternative therapies, to help inform and guide women as to which options are most likely to be beneficial to them. Few (...) complementary and alternative treatment options have proven evidence of effectiveness, but although many options do not stand up to scrutiny from a robust and evidence based perspective there will be individual women who will benefit from some of these treatments. Placebo effect is not inconsiderable and in menopausal studies will play a part in individual experience and reported benefits The full statement, scientific papers, charts, presentations etc are available in the . If you are not a member you can

2017 British Menopause Society

57. Menopause and hormone therapy

Menopause and hormone therapy Menopause and hormone therapy Approved by the Danish Society of Obstetrics and Gynecology March, 20 – 2017 Based on the NICE guideline Menopause and hormone therapy 1 Summary of clinical recommendations Hormone therapy can be considered for menopause related symptoms after thorough advice on the benefits and risks of treatment. Treat with the lowest possible dose in the shortest possible time, and preferably with dermal application. A Postmenopausal women suffering (...) from moderate to severe hot flushes are recommended to try lifestyle changes for a 3-month period and should undergo investigation of the risk factors of cardiovascular disease. If the lifestyle changes do not remedy the symptoms, one should treat based on whether the findings of the investigation into cardiovascular disease suggest low ( 10%) risk. Women at high risk of developing cardiovascular disease are advised against hormone therapy. Women that started menopause less than 10 years ago

2017 Nordic Federation of Societies of Obstetrics and Gynecology

58. Cardiotoxicity of Aromatase Inhibitors and Tamoxifen in Post-Menopausal Women with Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. (PubMed)

Cardiotoxicity of Aromatase Inhibitors and Tamoxifen in Post-Menopausal Women with Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Aromatase inhibitors (AIs) have been associated with cardiovascular disease in adjuvant randomized controlled trials (RCTs) comparing these drugs to tamoxifen. However, it is unclear whether this risk is real or due to cardioprotective effects of tamoxifen. To address this question, we conducted a systematic review and meta

Full Text available with Trip Pro

2016 Annals of oncology : official journal of the European Society for Medical Oncology

59. Non-Pharmacologic Treatments for Vasomotor Symptoms Associated with Menopause

Non-Pharmacologic Treatments for Vasomotor Symptoms Associated with Menopause Management Briefs eBrief-no117 -- Enter search terms Button to search HSRD ® Inside VA Budget and Performance Inside the News Room National Observances Special Events » » » » » Management Briefs eBrief-no117 -- Health Services Research & Development Management eBrief no. 117 » Issue 117 October 2016 The report is a product of the VA/HSR&D Evidence Synthesis Program. Evidence Report: Non-Pharmacologic Treatments (...) for Vasomotor Symptoms Associated with Menopause Vasomotor symptoms (VMS), which include hot flashes and night sweats, are the most common symptoms reported during the menopausal transition. VMS symptoms are experienced by as many as 80% of women with a mean age of onset of 51 years, and can last more than seven years. VMS can lead to increased healthcare encounters for symptom relief and reductions in quality of life. The degree to which VMS are bothersome is determined not only by how frequently

2016 Veterans Affairs - R&D

60. Association of Age at Onset of Menopause and Time Since Onset of Menopause With Cardiovascular Outcomes, Intermediate Vascular Traits, and All-Cause Mortality: A Systematic Review and Meta-analysis. (PubMed)

Association of Age at Onset of Menopause and Time Since Onset of Menopause With Cardiovascular Outcomes, Intermediate Vascular Traits, and All-Cause Mortality: A Systematic Review and Meta-analysis. As many as 10% of women experience natural menopause by the age of 45 years. If confirmed, an increased risk of cardiovascular disease (CVD) and all-cause mortality associated with premature and early-onset menopause could be an important factor affecting risk of disease and mortality among middle (...) -aged and older women.To systematically review and meta-analyze studies evaluating the effect of age at onset of menopause and duration since onset of menopause on intermediate CVD end points, CVD outcomes, and all-cause mortality.Medical databases (ie, Medline, EMBASE, and Web of Science) until March 2015.Studies (ie, observational cohort, case-control, or cross-sectional) that assessed age at onset of menopause and/or time since onset of menopause as exposures as well as risk of cardiovascular

Full Text available with Trip Pro

2016 JAMA cardiology